BRIEF published on 04/17/2026 at 21:05, 4 months 24 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 4 months 24 days ago Informations privilégiées / Autres communiqués Innate Pharma présentera des résultats intermédiaires de l'essai de Phase 2 MATISSE évaluant IPH5201 lors d'une session plénière dédiée aux essais cliniques au congrès de l'AACR 2026 Essai Clinique Cancer Du Poumon Innate Pharma AACR 2026 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 4 months 24 days ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
BRIEF published on 04/13/2026 at 07:05, 4 months 29 days ago Innate Pharma : Mise à Jour du Capital et des Droits de Vote Droits De Vote Biotechnologie Actions Immunothérapie Innate Pharma
BRIEF published on 04/13/2026 at 07:05, 4 months 29 days ago Innate Pharma Updates Share and Voting Rights as of April 2026 Biotechnology Shares And Voting Rights Innate Pharma April 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 4 months 29 days ago Innate Pharma met à jour ses actions et ses droits de vote à compter d'avril 2026 Biotechnologie Innate Pharma Actions Et Droits De Vote Avril 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 4 months 29 days ago Innate Pharma: Capital and Voting Rights Update Voting Rights Biotechnology Actions Immunotherapy Innate Pharma
PRESS RELEASE published on 04/13/2026 at 07:00, 4 months 29 days ago Inside Information / Other news releases Innate Pharma to hold its Annual General Meeting of shareholders on May 21, 2026 at 10:30 a.m. CEST in Marseille. Shareholders must register shares by May 14, 2026, 00:00 Paris time, to attend Annual General Meeting Shareholders Registration Innate Pharma Marseille
PRESS RELEASE published on 04/13/2026 at 07:00, 4 months 29 days ago Informations privilégiées / Autres communiqués Innate Pharma a publié le nouveau nombre d'actions et de droits de vote au 9 avril 2026 conformément aux règlements de l'AMF. Découvrez les détails dans le communiqué de presse Droits De Vote Actions AMF Communiqué De Presse Innate Pharma
PRESS RELEASE published on 04/13/2026 at 07:00, 4 months 29 days ago Inside Information / Other news releases Innate Pharma releases total shares and voting rights as of April 9, 2026, in compliance with French regulations. Learn about its innovative immunotherapies for cancer patients Voting Rights Shares French Regulations Innate Pharma Immunothérapies
Published on 09/12/2026 at 02:35, 11 hours 32 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 7 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 2 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 42 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 7 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 36 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 51 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 56 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 22 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 51 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
